As of now, the Chinese National Medical Products Administration (NMPA) approved 3 anti PD-1/L1 therapies (nivolumab, pembrolizumab, atezolizumab) for the management of driver-negative advanced or metastatic NSCLC, given their superior efficacy in prolonging survival over traditional chemotherapies (Herbst et al., 2016; Rittmeyer et al., 2017; Wu et al., 2019). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.